Startseite>>Signaling Pathways>> Chromatin/Epigenetics>> Histone Demethylases>>KDOAM-25 citrate

KDOAM-25 citrate

Katalog-Nr.GC38709

KDOAM-25-Citrat ist ein potenter und hochselektiver Inhibitor der Histon-Lysin-Demethylase 5 (KDM5) mit IC50-Werten von 71 nM, 19 nM, 69 nM, 69 nM fÜr KDM5A, KDM5B, KDM5C bzw. KDM5D. KDOAM-25-Citrat erhÖht die globale H3K4-Methylierung an Transkriptionsstartstellen und beeintrÄchtigt die Proliferation in MM1S-Zellen des multiplen Myeloms.

Products are for research use only. Not for human use. We do not sell to patients.

KDOAM-25 citrate Chemische Struktur

Größe Preis Lagerbestand Menge
10mM (in 1mL DMSO)
112,00 $
Auf Lager
5mg
102,00 $
Auf Lager
10mg
183,00 $
Auf Lager
50mg
714,00 $
Auf Lager
100mg
1.326,00 $
Auf Lager
200mg
2.447,00 $
Auf Lager
500mg
4.589,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

KDOAM-25 citrate is a potent and highly selective KDM5 sub-family of histone lysine demethylases inhibitor with IC50s of 71 nM, 19 nM, 69 nM, 69 nM for KDM5A, KDM5B, KDM5C, KDM5D, respectively. KDOAM-25 citrate increases global H3K4 methylation at transcriptional start sites and impairs proliferation in multiple myeloma MM1S cells[1].

[1]. Tumber A, et al. Potent and Selective KDM5 Inhibitor Stops Cellular Demethylation of H3K4me3 at Transcription Start Sites and Proliferation of MM1S Myeloma Cells. Cell Chem Biol. 2017 Mar 16;24(3):371-380.

Bewertungen

Review for KDOAM-25 citrate

Average Rating: 5 ★★★★★ (Based on Reviews and 38 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for KDOAM-25 citrate

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.